Fixed-dose combination · Metabolic / Diabetes

Synjardy

Empagliflozin and metformin hydrochloride
CombinationSGLT2 inhibitor + biguanide (fixed-dose combination)
Empagliflozin
PubChem CID 11949646
Metformin
PubChem CID 4091

Drag to rotate. Scroll or pinch to zoom.

Combines two diabetes medicines in one tablet: empagliflozin, which makes the kidneys pass extra sugar out in the urine, and metformin, which tells the liver to release less sugar into the blood and helps the body use insulin more effectively.

How it works

Synjardy puts two diabetes medicines into one tablet, and they work in different places in the body. Empagliflozin acts on the kidneys, telling them to let extra sugar pass out in the urine instead of being reabsorbed back into the blood. Metformin works on the liver and muscles instead, telling the liver to release less sugar into the blood and helping the body use insulin more effectively. Because the two act on different systems, combining them controls blood sugar better than either alone.

What it’s used for

Synjardy is prescribed, alongside diet and exercise, to help adults and children 10 and older with type 2 diabetes manage their blood sugar using two medicines in one pill instead of two separate prescriptions. Because it contains metformin, it carries a boxed warning — the FDA's strongest safety warning — about a rare but serious condition called lactic acidosis.

Mechanism
SGLT2 + biguanide (fixed-dose combination)
Drug class
Fixed-dose combination
Therapeutic area
Metabolic / Diabetes

Contains